ENDS advertising expenditures in English language media in the USA, 2015-2020.
Advertising and Promotion
Electronic nicotine delivery devices
Tobacco industry
Journal
Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612
Informations de publication
Date de publication:
16 Aug 2022
16 Aug 2022
Historique:
received:
18
01
2022
accepted:
19
06
2022
pmc-release:
16
02
2024
entrez:
16
8
2022
pubmed:
17
8
2022
medline:
17
8
2022
Statut:
aheadofprint
Résumé
Electronic nicotine delivery system (ENDS) advertising is associated with ENDS purchase and use. This study assessed trends in ENDS advertisement (ad) expenditures in the USA from 2015 to 2020 overall, by media channel and by advertiser. Data came from Numerator, which conducts surveillance of ads and estimates expenditures. The estimates are dollars spent (adjusted to 2020) by the advertiser for each ad occurrence for print, radio, television and digital (online, mobile) media channels. ENDS ad expenditures were assessed by quarter, media channel and the top five advertisers based on ad occurrences. Overall ENDS ad expenditures increased from $38 million in 2015 to $217 million in 2019 before decreasing to a low of $22 million in 2020. By media channel, print expenditures led the channels with more than twice as much spent as television, four times more than radio and 10 times more than digital. By advertiser, JUUL led in ENDS ad expenditures from 2015 to 2020 with almost $189 million spent, followed by British American Tobacco (BAT, $105 million) and Imperial Tobacco ($62 million). Overall ad expenditures were relatively stable from 2015 to mid-2018 when large expenditures by JUUL and subsequent expenditures by BAT and Imperial Tobacco led to expenditure highs in 2019. E-cigarette and vaping-associated lung injury (EVALI), the JUUL self-imposed ad suspension and COVID-19 likely all played a role in advertising lows in 2020. The absence of popular Puff Bar brand ads from the traditional media channels studied highlights the importance of monitoring direct and indirect advertising on newer media channels like social media.
Sections du résumé
BACKGROUND
BACKGROUND
Electronic nicotine delivery system (ENDS) advertising is associated with ENDS purchase and use. This study assessed trends in ENDS advertisement (ad) expenditures in the USA from 2015 to 2020 overall, by media channel and by advertiser.
METHODS
METHODS
Data came from Numerator, which conducts surveillance of ads and estimates expenditures. The estimates are dollars spent (adjusted to 2020) by the advertiser for each ad occurrence for print, radio, television and digital (online, mobile) media channels. ENDS ad expenditures were assessed by quarter, media channel and the top five advertisers based on ad occurrences.
RESULTS
RESULTS
Overall ENDS ad expenditures increased from $38 million in 2015 to $217 million in 2019 before decreasing to a low of $22 million in 2020. By media channel, print expenditures led the channels with more than twice as much spent as television, four times more than radio and 10 times more than digital. By advertiser, JUUL led in ENDS ad expenditures from 2015 to 2020 with almost $189 million spent, followed by British American Tobacco (BAT, $105 million) and Imperial Tobacco ($62 million).
CONCLUSIONS
CONCLUSIONS
Overall ad expenditures were relatively stable from 2015 to mid-2018 when large expenditures by JUUL and subsequent expenditures by BAT and Imperial Tobacco led to expenditure highs in 2019. E-cigarette and vaping-associated lung injury (EVALI), the JUUL self-imposed ad suspension and COVID-19 likely all played a role in advertising lows in 2020. The absence of popular Puff Bar brand ads from the traditional media channels studied highlights the importance of monitoring direct and indirect advertising on newer media channels like social media.
Identifiants
pubmed: 35973789
pii: tc-2022-057279
doi: 10.1136/tc-2022-057279
pmc: PMC10514744
mid: NIHMS1931636
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : FDA HHS
ID : U01 FD005942
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Fed Regist. 2016 May 10;81(90):28973-9106
pubmed: 27192730
Addiction. 2020 Dec;115(12):2357-2368
pubmed: 32285978
Nicotine Tob Res. 2019 Jan 1;21(1):14-24
pubmed: 29315420
J Adolesc Health. 2020 Jan;66(1):64-71
pubmed: 31383392
Tob Control. 2015 Mar;24(2):110-1
pubmed: 24789603
Tob Control. 2022 Sep;31(5):655-658
pubmed: 34059551
MMWR Morb Mortal Wkly Rep. 2014 Jun 27;63(25):542-7
pubmed: 24964880
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1310-1312
pubmed: 32941408
Tob Control. 2020 Dec;29(e1):e124-e126
pubmed: 32108086
Public Health Nurs. 2017 Sep;34(5):430-436
pubmed: 28485553
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1736-1742
pubmed: 33211681
Addiction. 2021 May;116(5):1212-1223
pubmed: 33271632
Tob Control. 2022 Jan;31(1):7-10
pubmed: 33051277